PR97014

NORTH CHARLESTON, S.C., July 18, 2022 /PRNewswire=KYODO JBN/ --

SHL Medical (hereinafter referred to as "SHL") has revealed plans for a new

manufacturing site in the US, in response to the growing market demand for its

autoinjector product portfolio. The decision stems from SHL's strategic

assessments in extending its production to North America.

Photo - https://mma.prnewswire.com/media/1858961/SHL_Medical_SC.jpg

The new US site will be located in North Charleston, South Carolina, and will

boast approximately 25,000 m(2) (270,000 ft(2)). With initial investments of

US$ 90 million, SHL is expected to create an estimate of 165 local employment

opportunities. Operations are expected to launch by 2024.

The South Carolina site will be an advanced facility with medical device

injection molding and fully automated assembly capabilities. Together with

SHL's current final assembly, labeling, and packaging operations in Deerfield

Beach, Florida, the expanded manufacturing capabilities in the US will further

fortify SHL's offerings in delivering comprehensive services to its partners.

In 2019, SHL developed a long-term strategy in response to the growing

autoinjector demand and to meet future manufacturing needs. The announcement of

the new US operation aligns with the company's ongoing expansion, including a

new Swiss site already being announced (

https://c212.net/c/link/?t=0&l=en&o=3593771-1&h=1810659832&u=https%3A%2F%2Fwww.shl-medical.com%2Fshl-medical-reveals-plans-to-set-up-manufacturing-site-in-zug-switzerland%2F&a=a+new+Swiss+site+already+being+announced

). The new production site in the US, which is to be realized preferentially

and accelerated, will offer fully automated production facilities and a

flexible supply chain with reduced distance to main markets.

Chairman and CEO Ulrich Faessler comments: "Demand for SHL's products has

increased significantly. Therefore, we are speeding up our plans for a new

plant in the US. Similar to our upcoming European site in Zug, Switzerland, the

US site will be a state-of-the-art, fully automated site. This expansion

signifies SHL's pledge to our advanced manufacturing strategy that will support

our sustainability goals; and, at the same time, risk-mitigate supply chain

disturbances through closer production with our customers, in light of various

global events from the past two years. This further supports our customers with

one-stop-shop capabilities, providing high-quality drug delivery systems to the

end-users – the patients."

Media Contact

Rylie Geraci  

BCW Global

rylie.geraci@bcw-global.com

SOURCE: SHL Medical